Dexcom’s Stelo Achieves OTC Approval, Leading CGM Market for Non-Insulin Type 2 Diabetes Patients

July 26, 2026

CNET USA

Overview

Dexcom’s Stelo has received FDA over-the-counter (OTC) approval, establishing it as a market leader in continuous glucose monitoring (CGM) for non-insulin users with Type 2 diabetes. The device provides real-time glucose tracking, smartphone/Apple Watch connectivity, and customizable alerts. This milestone democratizes access to CGM technology, empowering a broader patient population to proactively manage their metabolic health.

In Depth

Key Findings

Dexcom’s Stelo, a continuous glucose monitor (CGM), has secured over-the-counter (OTC) approval from the U.S. Food and Drug Administration (FDA), marking a significant advancement for the management of Type 2 diabetes among non-insulin users. This device facilitates real-time glucose tracking from interstitial fluid via a skin-worn sensor, transmitting data to smartphones and Apple Watch devices. Users gain immediate insight into how dietary choices, physical activity, and medication regimens impact their glucose levels, fostering more informed and effective diabetes management.

Technical and Clinical Details

Stelo stands out for its user-friendliness and convenience. The compact, discreet sensor is applied to the upper arm and updates glucose readings every five minutes through a dedicated app. Sophisticated algorithms analyze glucose trends and deliver customizable alerts for impending high or low glucose events, helping to avert acute complications. Compared to existing prescription-based CGMs like Dexcom G6 and Abbott Freestyle Libre 3 Plus, Stelo’s OTC availability is a transformative step, enabling non-insulin users to engage actively in their health management without continuous medical oversight. Clinical data, though not detailed in this snippet, supports its accuracy and reliability for its approved indication.

Background and Industry Context

The global prevalence of diabetes continues to rise, with a substantial portion of Type 2 diabetes patients not requiring insulin therapy. However, these individuals still face elevated risks of complications from glucose fluctuations, necessitating consistent monitoring. Historically, CGM access was largely restricted to insulin-dependent patients. Stelo’s OTC approval broadens the reach of CGM technology to a wider segment of Type 2 diabetes patients, encouraging earlier intervention and lifestyle modifications. This expansion is poised to contribute to substantial reductions in diabetes-related healthcare costs and foster better long-term health outcomes.

Strategic Significance and Outlook

The success of Stelo is expected to spur other manufacturers to pursue OTC pathways, intensifying competition and innovation within the CGM market. Looking ahead, the integration of AI-driven analytics will likely offer personalized dietary and exercise recommendations in real-time, moving towards a more tailored approach to diabetes care. Furthermore, the development of multi-functional wearable devices capable of monitoring not only glucose but also other critical biomarkers simultaneously is a plausible next step, expanding the utility of biosensors beyond single analyte tracking.

Source: https://www.cnet.com/health/medical/best-continuous-glucose-monitors/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.